Abstract Library

#869 Phase 1 Expansion Study of an Oral TORC1/TORC2 Kinase Inhibitor (CC-223) in Non-Pancreatic Neuroendocrine Tumors (NET)

Introduction: Clinical efficacy of everolimus, an allosteric TORC1-selective inhibitor, has been established in pancreatic NET. CC-223 is an ATP-competitive inhibitor of the mTOR kinase, inhibiting both TORC1 and TORC2.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Meyer T, Mahipal A, Bendell J, Nemunaitis J, Mita M,

Keywords: TORC-1 CC-223,

#265 A Novel PKCßII Inhibitor Induces Antiproliferative Effects in Human Pancreatic Neuroendocrine Tumor Cells

Introduction: Deregulation of the protein kinase C (PKC) signaling pathway has been implicated in tumor progression.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Molè D, Gagliano T, Gentilin E, Bondanelli M, Tagliati F,

Keywords: PKCßII, selective inhibitor, human pancreatic neuroendocrine cell line,